4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 78 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,251 | +4.4% | 2,612 | +48.2% | 0.00% | 0.0% |
| Q2 2023 | $31,839 | +5.1% | 1,762 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $30,289 | -34.7% | 1,762 | -15.6% | 0.00% | 0.0% |
| Q4 2022 | $46,352 | +176.3% | 2,087 | 0.0% | 0.00% | +100.0% |
| Q3 2022 | $16,779 | +15.2% | 2,087 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $14,567 | -53.8% | 2,087 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $31,555 | -82.6% | 2,087 | -74.8% | 0.00% | -50.0% |
| Q4 2021 | $181,751 | +11.6% | 8,284 | +37.2% | 0.00% | 0.0% |
| Q3 2021 | $162,818 | +25.8% | 6,037 | +102.3% | 0.00% | 0.0% |
| Q1 2021 | $129,446 | – | 2,984 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 377,777 | $15,659,000 | 5.43% |
| BVF INC/IL | 1,106,070 | $45,847,000 | 1.80% |
| Eagle Health Investments LP | 50,000 | $2,073,000 | 1.33% |
| Ally Bridge Group (NY) LLC | 150,000 | $6,218,000 | 1.07% |
| Casdin Capital, LLC | 780,555 | $32,354,000 | 0.96% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $163,227,000 | 0.45% |
| Pinz Capital Management, LP | 19,900 | $825,000 | 0.38% |
| ArrowMark Colorado Holdings LLC | 1,063,744 | $44,092,000 | 0.34% |
| Perceptive Advisors | 600,256 | $24,881,000 | 0.27% |
| ACUTA CAPITAL PARTNERS, LLC | 20,000 | $829,000 | 0.23% |